Search

everythinglearnresearchcommunity

for

Search:↓

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.

The conversation discusses exploring new hair loss treatments beyond popular ones like Finasteride, Minoxidil, and Ketoconazole. Specific treatments mentioned include ozone therapy, Dutasteride mesotherapy, RegeneraActiva, microcurrent electrical hair stimulation, Nourkrin, and BioEqua Enercharger.

A natural sugar called 2dDR may stimulate hair growth and is comparable to minoxidil, but it's not widely available for purchase. Concerns about minoxidil's safety for pets were discussed, with some users seeking alternatives.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user is sharing their progress with hair loss treatments including finasteride, minoxidil, keto shampoo, and dermastamping. Other users are expressing positive reactions and discussing the benefits of keto shampoo and minoxidil.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The user noticed increased hair shedding after switching to a new Kirkland minoxidil with a different formula and is concerned about its effectiveness. They suspect the shedding might be linked to the new minoxidil rather than other factors like changing finasteride dosage or stopping RU58841.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

Choosing between KB and PG solutions for applying RU58841, considering factors like scalp oiliness and absorption. Some users prefer KB for being gentler, while others use PG and recommend washing hair before application for better results.

Oral Minoxidil users discuss whether caffeine affects its effectiveness due to adenosine receptor blockade. Users report no significant impact on hair growth despite caffeine consumption.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. User feedback suggests 2-deoxy-D-ribose is ineffective.

The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.

The user experiences side effects from minoxidil and is considering alternatives like stemoxydine and adenosine for hair regrowth and density, but finds options like caffeine and various oils unreliable. They are also using a 5AR inhibitor (finasteride).

A 23-year-old male switched to a topical solution containing Fin 0.1% and Min 5% from a previous solution with Fin 1% and Min 5%, noticing increased hair shedding. He is concerned about losing around 50 hairs while using ketoconazole shampoo.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

A user who has been using finasteride and minoxidil, as well as a keto shampoo for two and a half months, and believes they are seeing slight improvements in their hair loss.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.

User DeadRay9 reports good progress on finasteride and ketoconazole, with irregular microneedling. They take 1.25mg finasteride, experienced increased libido, and saw improvements at 3-5 months.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

A user is seeking recommendations for a shampoo with 1% Ketoconazole that is sulfate-free. They are looking for a product without 'sodium laureth sulfate.'

A user noticed their hair became curly after using ketoconazole shampoo and wonders if the shampoo caused the change. They like the new curls and want to maintain them.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.